Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will report third-quarter 2026 financial results and provide a business update November 4, giving investors an opportunity to assess the Malvern-based biotechnology company’s …
Ocugen Sets November 4 Earnings Report as Gene Therapy Advances Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has signed a licensing agreement with Roots Pharmaceutical that could generate up to $259 million in upfront and milestone payments, plus royalties, giving …
Ocugen Signs Gene Therapy Deal Worth Up to $259 Million Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) has established a European affiliate in Amsterdam and appointed former Moderna Netherlands executive Jolanda Crombach to lead it, positioning the Malvern biotechnology company …
Ocugen Expands Into Europe Ahead of Gene Therapy Filings Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) Chief Executive Officer Shankar Musunuri will discuss regulatory approval and commercialization of cell and gene therapies at an industry conference Oct. 6 in …
Ocugen CEO to Address Gene Therapy Commercialization Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has secured provisional approval and priority designation in The Bahamas for OCU400, creating a pathway to provide its investigational gene therapy to retinitis …
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has dosed the first patient in a global Phase 3 trial of OCU410, moving its one-time gene therapy for geographic atrophy into pivotal …
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will present 12-month Phase 2 results for its OCU410 gene therapy in geographic atrophy at a scientific meeting in September, putting new clinical …
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) extended its expected cash runway into 2028 with a $130 million convertible debt financing as the biotechnology company moves one retinal gene therapy …
Ocugen Raises $130 Million as Gene Therapy Trials Advance Read More MALVERN, PA — The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Ocugen Inc.’s experimental OCU410 gene therapy for geographic atrophy, giving the blindness treatment access …
FDA Gives Ocugen Gene Therapy Expedited Regulatory Status Read More MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will report second-quarter 2026 financial results before the market opens Aug. 6 and hold a conference call later that morning to discuss its …
Ocugen Sets Aug. 6 Earnings Call With Business Update Read More